Tackling The Key Challenges In Viral Vector Manufacturing

By Eduard Ayuso, Chief Technology Officer, Siegfried DINAMIQS

Viral vectors are the foundation of many cell and gene therapies, yet translating promising candidates into commercially viable treatments remains a significant manufacturing challenge. Developers must balance two competing demands: achieving high yields to support scalability and cost efficiency while maintaining the quality attributes essential for safety and therapeutic performance.

Success depends on optimizing both upstream and downstream processes. Factors such as cell selection, plasmid design, productivity, purification strategies, and impurity removal all influence the final product. At the same time, advanced analytical capabilities are becoming increasingly critical. Early integration of analytics can provide deeper process understanding, enable faster troubleshooting, and support data-driven optimization before issues affect later-stage development.

As cell and gene therapies mature, manufacturers need scalable, flexible approaches that combine productivity, quality, and robust process insight. Explore key considerations for overcoming viral vector manufacturing challenges and supporting successful clinical and commercial development.